Key Highlights
- BSX shares fell to a 52-week bottom of $60.54, representing approximately 35–36% decline since January
- Investment firm Stifel reduced its price objective from $90 down to $85 based on electrophysiology purchasing trends before the April 22 quarterly report
- First quarter 2026 financial results scheduled for release on April 22, 2026
- Several Wall Street firms continue recommending Buy/Outperform ratings while adjusting targets downward — RBC maintains $115 objective, UBS stays at $105
- InvestingPro identifies BSX among its Most Undervalued stocks with a calculated Fair Value of $76.66
Shares of Boston Scientific have experienced significant turbulence throughout 2026. The medical device manufacturer saw BSX hit a 52-week bottom at $60.54 on April 21, with current trading levels hovering between $60.43 and $60.99 — representing a substantial retreat from its 52-week peak of $109.50.
Boston Scientific Corporation, BSX
This represents approximately a 36% year-to-date decline, wiping out significant value from the company’s $90.6 billion market capitalization.
Rick Wise, analyst at Stifel, decreased his price objective on BSX to $85 from a previous $90 in anticipation of the company’s first-quarter 2026 financial disclosure, scheduled for April 22, 2026. His Buy recommendation remains unchanged.
The adjustment stems from monthly electrophysiology (EP) hospital purchasing information that Stifel utilizes to forecast quarterly performance before official announcements.
January figures showed approximately 92% completion, February reached roughly 85%, and March stood at about 60% — providing a substantial yet incomplete view of EP revenue trajectories.
According to this purchasing data, Stifel concludes BSX’s Q1 US EP consensus revenue expectation of approximately $587 million falls “within the band of achievability.” While not overly optimistic, this assessment doesn’t signal immediate concern.
Stifel’s analysis incorporated comparisons with Johnson & Johnson and Abbott Laboratories, utilizing the identical EP purchasing database to validate projected versus reported revenues. The research firm had previously identified potential downside exposure to US EP consensus figures ahead of last quarter’s report using comparable methodology.
Wall Street Price Objectives Remain Significantly Higher
Notwithstanding the negative momentum, financial analysts haven’t completely retreated from their positions. Truist Securities maintained its Buy recommendation while trimming its objective to $90 from $92. The institution anticipates cardiovascular segment expansion of 8.5% to 9% in the forthcoming quarterly disclosure.
RBC Capital reaffirmed an Outperform rating accompanied by a $115 price objective following direct conversations with BSX management regarding expansion opportunities.
UBS retained its Buy rating and $105 target after reviewing CHAMPION-AF clinical trial outcomes for the Watchman cardiac implant. The study achieved all primary and secondary objectives — a favorable result that UBS believes mitigates headline concerns.
However, there’s a complication. The Watchman device demonstrated a marginally elevated ischemic stroke incidence when compared to non-vitamin K antagonist oral anticoagulants (NOACs), which disappointed certain market participants.
Piper Sandler preserved its Overweight rating after consulting with a high-volume electrophysiologist who anticipates increased Watchman adoption notwithstanding the stroke statistics.
Shares Identified as Trading Below Intrinsic Value
InvestingPro has designated BSX among its most undervalued equity positions, establishing its Fair Value at $76.66 — approximately 27% higher than present trading levels.
Revenue expansion has maintained momentum, with BSX delivering nearly 20% growth throughout the trailing twelve months. This represents a fundamentally sound operation experiencing market pressure rather than operational deterioration.
Market attention now shifts to April 22, when BSX releases Q1 2026 financial results. This report will provide the initial substantive validation of whether EP revenue performance aligned with Stifel’s data-driven projections.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
